Liquid Biopsy is a convenient, fast, and non-invasive sampling technique that can show the changes in tumour gene profile & provide a robust base for individual therapy & early diagnosis of cancer. The demand for liquid biopsy is arising significantly for the detection & isolation of circulating tumour DNA, RNA, and exosomes to diagnose the recurrence of cancerous cells in the treatment process.
Market Insights & Analysis: EMEA Liquid Biopsy Market (2023-28):
The EMEA Liquid Biopsy Market is projected to grow at a CAGR of around 13.98% during the forecast period, 2023-28. The market noticed consistent growth since the past few years, owing to the increasing prevalence of cancer patients coupled with a surge in demand for minimally invasive & fast diagnostic tests for detection. The rising prevalence of cancer has affected patients in the EMEA region, owing to the sedentary lifestyle, harmful carcinogenic elements in the environment, etc. According to the World Health Organisation (WHO), there were around 4 million cancer cases in Europe in 2020, of which nearly 2.4 million cases were in men & over 2.1 million in women.
|Study Period||Historical Data: 2018-21|
|Base Year: 2022|
|Forecast Period: 2023-28|
|Country Covered||Germany, The UK, France, Italy, Spain, Saudi Arabia, The UAE, Egypt, South Africa, Rest of Europe Middle East & Africa|
|Key Companies Profiled||Thermofisher Scientific, Hoffmann-La Roche Ltd, Sysmex Corporation, Qiagen N.V., Guardant Health, Bio Rad, Neo Genomics, Epigenomics, Menarini-Silicon Biosystems, Agena Bioscience Inc., Silicon Biosystems, Pathway Genomics Corporation, Illumina Inc., Myraid Genetics., Others|
|Unit Denominations||USD Million/Billion|
Moving forward, it is presumed that these cases would elevate in the coming years. Hence, this has affected the consciousness of the population & due to this individual are becoming more aware of early diagnosis & the treatment of the diseases. In response to this demand, various healthcare institutions are developing liquid biopsy test procedures for the early detection of cancer among patients. For instance, in 2023, Vall d’Hebron Institute of Oncology (VHIO) in Barcelona integrated Liquid Biopsy Testing for cancer patients to help healthcare professionals make more informed treatment decisions. These developments are supplementing the demand for liquid biopsy & have the potential to accelerate the EMEA Liquid Biopsy Market growth in the forecast year as well.nderstanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks & optimize their operations.
EMEA Liquid Biopsy Market Drivers:
Prevalence in the Number of Cancer Patients Would Generate the Demand for Liquid Biopsy – Cancer has been a chronic disease over the past years & would continue to ascend in the forecasting year as well, owing to the increasingly sedentary lifestyle, smoking, and drinking habit of the individual, which would require better diagnostic facilities, treatment, and care for the patients. The continuous boost in the number of cancer patients emphasizes the need for accurate & convenient diagnostic systems for early cancer detection. Consequently, with the rising number of cancer patients, especially across Turkey, France, Denmark, etc., the usage of Liquid Biopsy is also uplifting. The advantages of liquid biopsy, like lower cost, early prognosis, therapy monitoring, etc., have further enhanced their adoption over conventional diagnostic methods to detect urothelial carcinoma, non-urological cancers, and other blood cancers.
The use of liquid biopsy has also been upscale to determine the best treatments for cancer patients, especially lung & prostate cancer, in which the patient receives specific targeted drugs. Hence, the improved investments by government organizations & pharmaceutical companies to escalate the research & development of new cancer treatments are anticipated to augment the growth of the EMEA Liquid Biopsy Market during the forecasted period.
EMEA Liquid Biopsy Market Opportunities:
Development of Enhanced Medical Infrastructure & Boost in Medical Tourism Activities – The surge in the development of advanced medical infrastructure comprising specialty clinics & hospitals in emerging economies such as India, China, Egypt, Brazil, etc., is expected to offer potential growth opportunities for the key players operating in the EMEA Liquid Biopsy Market. This is attributed to the growing prevalence of cancer diseases such as skin, breast, pancreatic, etc., increasing medical expenditure for preventive care & a rise in medical tourism activities in these economies. For instance, in 2022, United State Agency for International Development (USAID) announced a USD415 million collaboration to accelerate primary healthcare access across Côte d’Ivoire, Ghana, Kenya, Malawi, and Nigeria. This, in turn, is anticipated to boost the patient’s accessibility to primary healthcare & preventive disease diagnosis, which would create an opportunity for liquid biopsy to aid early detection & effective management of cancer diseases in the future years.
EMEA Liquid Biopsy Market Challenges:
Ascending Accuracy Concerns with Rise in the Number of False Negative Results – The detection of tumor cells in the sample for the precise diagnosis requires skilled professionals as the number of ctDNA in any particular cancer mutation is low in the blood of the cancer patient, especially after any treatment or surgery, which makes the detection of ctDNA in liquid biopsy difficult. According to sampling statistics, there may be fewer detectable cancer mutations containing ctDNA in the patient’s blood sample. As a result, ctDNA was present in the sample but at a low level, and thus couldn’t be detected in the test. This affects the test result of the liquid biopsy testing for cancer by producing false negative results where ctDNA is present but not identified. False negatives can occasionally result in a tumor's recurrence not being discovered at an early stage. Therefore, these create accuracy concerns in the results, which generates doubt in clinicians & can cause impediments in the growth of the EMEA Liquid Biopsy Market.
EMEA Liquid Biopsy Market Trend:
Rising Use of ctDNA to Enhance the Accuracy of Liquid Biopsy – Liquid biopsy has the potential to improve the treatment for patients who are diagnosed with cancer. However, researchers are exploring the potential use of ctDNA for early detection & symptoms of tumors in the blood. For instance, GRAIL (Gene recognition and analysis internet link) has developed a multi-cancer blood test-based DNA methylation pattern in ctDNA. This technology enables the identification & treatment of cancer at an earlier stage when the treatment is likely to be more effective & chances of survival are high. In addition, it allows us to shift the drugs that are currently being trailed in the last stage of cancer into the early stages of the disease, helping to build more effective cancer treatment. Thus, liquid biopsy technology coupled with ctDNA analysis is the emerging technology that would certainly augment the revenue growth of the EMEA Liquid Biopsy Market in the coming years.
EMEA Liquid Biopsy Market (2023-28): Segmentation Analysis
The EMEA Liquid Biopsy Market study of MarkNtel Advisors evaluates & highlights the major trends & influencing factors in each segment & includes predictions for the period 2023–2028 at the, regional & national levels. Based on the analysis, the market has been further classified as:
By Circulating Biomarker:
Circulating Tumour DNA (CTDNA) markers are anticipated to gain significant market share in forecasted years, as they provide opportunities for molecular diagnosis of cancer to analyze tumor progression & recurrence. CTDNA analysis offers a less invasive alternative to other kinds of circulating biomarkers & a more representative method to unveil the genomic landscape of newly diagnosed multiple myeloma. This non-invasive approach enables early detection of cancer, monitoring of disease progression, and assessment of treatment response, ultimately leading to better patient outcomes. Furthermore, to cater to the surging demand & grab substantial revenue opportunities, companies such as Illumina, and Guardant Health, among others, are actively investing in R&D to develop advanced CTDNA biomarkers. Hence, the increasing research activities to identify the future potentials of CTDNA markers also uplifted their demand among research organizations across the region, further contributing to enhancing the EMEA Liquid Biopsy Market.
By Sample Type:
Blood Sample-based Testing dominated the EMEA Liquid Biopsy Market during the historical years, as it is highly preferred by cancer patients owing to its least invasive nature & reduced risk of incision into the body. The blood samples can be used to detect various biomarkers like ctDNA, CTC, etc., and also allows for reducing the cost & time for the diagnosis. Further, the collection of blood samples is the most convenient method of diagnosis & has been majorly used for the detection of brain, lung, and breast cancers across the region, as it is one of the most painless methods of cancer detection. In addition to this, it can also detect the recurrence of cancer after treatment & helps in early detection & blood-based tests ongoing research for cancer is expected to drive the market in upcoming years.
Further, the demand for blood-based testing also arises among cancer research organizations, as they mainly use blood samples to determine the potential of liquid biopsies in cancer diagnostics. In 2022, the European Liquid Biopsy Society announced an IMI-funded CANCER-ID project, allowing us to identify & overcome hurdles linked with blood-based biopsies for detecting & monitoring tumors, hence contributing to the market growth.
EMEA Liquid Biopsy Market (2023-28): Regional Projections
Geographically, the EMEA Liquid Biopsy Market expands across:
Germany is expected to account for the majority of market share during the forecast period 2023-28, as the country has the highest adoption rate of liquid biopsy due to various healthcare companies such as Roche, Qiagen N.V., and others working in the marketplace. Germany has the highest implementation of PCR, NGS, and other technologies.
However, the UK is also presumed to detect growth in the EMEA Liquid Biopsy Market due to the presence of several research institutes, such as the University of Oxford and the National Institute of Medical Research. The country is also expanding research activities by increasing a government initiative to modernize the healthcare infrastructure & rising healthcare expenditure. Additionally, strategic approvals & partnership between leading market players to promote this technology in the region is anticipated to fuel the EMEA Liquid Biopsy Market in the upcoming years.
EMEA Liquid Biopsy Testing Industry Recent Development:
Gain a Competitive Edge with Our EMEA Liquid Biopsy Market Report
Frequently Asked Questions
A. The EMEA Liquid Biopsy Market is expected to record around 13.98% CAGR during 2023-28.
A. The Circulating Tumor Cell Marker would create remunerative prospects for the key companies in the EMEA Liquid Biopsy Market.
A. Prevalence in the number of cancer patients would drive the EMEA Liquid Biopsy Market during 2023-2028.
A. The top players in the EMEA Liquid Biopsy Market are Thermofisher Scientific, Hoffmann-La Roche Ltd, Sysmex Corporation, Qiagen N.V., Guardant Health, Bio Rad, Neo Genomics, Epigenomics, Menarini-Silicon Biosystems, Agena Bioscience Inc., Silicon Biosystems, Pathway Genomics Corporation, Illumina Inc., Myraid Genetics., and others.
A. Germany is expected to emerge as a promising region for the EMEA Liquid Biopsy Market to witness profitable opportunities in the years ahead.
A. Ascending accuracy concerns with rise in the number of false negative results would act as a possible restraint affecting the growth of the EMEA Liquid Biopsy Market.
EMEA Liquid Biopsy Market Research Report (2023-2028) - Table of Contents